The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I-II study to evaluate safety and efficacy of the combination of niraparib plus cabozantinib in patients with advanced kidney/urothelial carcinoma.
 
Daniel E. Castellano
No Relationships to Disclose
 
Miguel A. Climent
Honoraria - Astellas Oncology; Bayer; Janssen; Sanofi
Consulting or Advisory Role - Bayer; Janssen; Sanofi
Travel, Accommodations, Expenses - Astellas Oncology; Janssen; Pfizer
 
Ignacio Duran
Honoraria - Bristol-Myers Squibb; Ipsen; Roche/Genentech
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; MSD Oncology; Roche/Genentech
Research Funding - Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Begona Mellado
No Relationships to Disclose
 
Jesus Paramio
Travel, Accommodations, Expenses - Janssen
 
Francisco X. Real
No Relationships to Disclose
 
Jose Luis Ramirez
No Relationships to Disclose
 
Juan Luis Sanz
No Relationships to Disclose
 
Albert Font Pous
No Relationships to Disclose